Abstract
The advent of targeted therapy presents an unprecedented opportunity for advances in the treatment of cancer. A key challenge will be to translate the undoubted promise of targeted agents into tangible clinical benefits. Achieving this goal is likely to be dependent upon a number of factors. These include continued research to improve our understanding of the heterogeneity and complexity of the tumour microenvironment; refinement of clinical trial design to incorporate nontraditional end points such as the optimum biological dose and health-related quality of life; and the use of technological advancements in proteomics, genomics and biomarker development to better predict tumour types and patient subsets that may be particularly responsive to treatment as well as enable a more accurate assessment of drug effect at the molecular level. In summary, the future success of targeted agents will require an integrated multidisciplinary approach involving all stakeholders. © 2005 Cancer Research UK.
| Original language | English |
|---|---|
| Pages (from-to) | S28-S31 |
| Journal | British Journal of Cancer |
| Volume | 92 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jun 2005 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antitumour
- Biomarker
- Clinical trial design
- Targeted therapy
Fingerprint
Dive into the research topics of 'Targeted antitumour therapy - Future perspectives'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver